[Form 4] Contineum Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Contineum Therapeutics, Inc. (CTNM) – Form 4 insider filing

On 26 June 2025, non-employee director Evert B. Schimmelpennink received a routine annual stock-option grant under the company’s 2024 Equity Incentive Plan. The award covers 14,750 shares of Class A Common Stock with an exercise price of $4.01 and expires on 25 June 2035. The option vests in full on the earlier of 26 June 2026 or the next regular annual shareholder meeting, contingent upon continuous board service.

The filing reports no open-market purchase or sale of shares; it solely reflects a compensatory grant made pursuant to the Board’s non-employee director compensation program. Following the grant, the director beneficially owns 14,750 derivative securities directly. No other transactions or changes in ownership were disclosed.

Because the transaction is part of a pre-established compensation policy and involves a small percentage of outstanding shares, it is unlikely to have a material impact on the company’s capital structure or near-term valuation.

Positive

• Alignment of interests: Option grant ties director compensation to future share performance, potentially supporting shareholder value.

Negative

• Marginal dilution: Additional 14,750 option shares add slight dilution, though impact is immaterial given company size.

Insights

Corporate Governance Analyst

TL;DR: Routine director option grant; aligns incentives, minimal dilution, neutral valuation impact.

The Form 4 discloses a standard non-employee director compensation event—14,750 options at $4.01, vesting within one year. Such grants are customary and represent a negligible fraction of CTNM’s share count, limiting dilution risk. Governance wise, the award reinforces board-shareholder alignment without signaling insider sentiment because no shares were bought or sold. Overall market impact is neutral; investors can view it as ordinary course housekeeping rather than a directional signal.

Portfolio Manager

TL;DR: Immaterial option grant; no trading by insider; ignore for position sizing.

From a portfolio perspective, this filing does not change the investment thesis. The option size is modest and falls within typical director compensation benchmarks. Absence of open-market activity means there is no fresh read-through on insider sentiment or liquidity needs. I treat the news as non-impactful to share supply-demand dynamics and would not adjust exposure based solely on this disclosure.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schimmelpennink Evert B.

(Last) (First) (Middle)

3565 GENERAL ATOMICS COURT, SUITE 200

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Contineum Therapeutics, Inc. [ CTNM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$4.01	06/26/2025		A		14,750		(1)	06/25/2035	Class A Common Stock	14,750	$0	14,750	D

Explanation of Responses:

1. Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 14,750 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2026, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service.

	/s/ Peter Slover, Attorney-in-Fact	06/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Contineum Therapeutics (CTNM) disclose in the latest Form 4?

The company reported granting director Evert B. Schimmelpennink options for 14,750 shares at an exercise price of $4.01.

When do the newly granted CTNM options vest?

They vest fully on the earlier of 26 June 2026 or the next annual shareholder meeting.

What is the expiration date of the CTNM director’s stock options?

The options expire on 25 June 2035.

Did the director buy or sell any CTNM shares in the market?

No. The Form 4 only reports a compensatory option grant; there were no open-market purchases or sales.

How many CTNM derivative securities does the director own after the grant?

The reporting person now beneficially owns 14,750 stock options directly.

Is the option grant part of a 10b5-1 trading plan?

The filing does not indicate that the transaction was made under Rule 10b5-1; the relevant box was not checked.